FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	/AL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e Responses)														
Name and Address of Reporting Person * Guy Wendy				2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. 1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106			CALS,	3. Date of Earliest Transaction (Month/Day/Year) 07/08/2021						_>	X_Officer (give title below) Other (specify below) Chief Administrative Officer)
(Street) HANOVER, MD 21076			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person nired, Disposed of, or Beneficially Owned						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					ies Acquirec							
(Instr. 3) Date		2. Transaction Date Month/Day/Year)	2A. Deemed Secution Date, if Code (Instrument) (Month/Day/Year)		Code (A) (Instr. 8) (Ins		R. Securities Acquired A) or Disposed of (D) Instr. 3, 4 and 5)		Transaction(s) (Instr. 3 and 4)		ed	Ownership of Form: Be Oirect (D) or Indirect (I)	eneficial wnership		
						С	ode	V Aı	nount (D)	Price				(Instr. 4)	
			ı	(e.g., puts,	calls,	warran	ts, oj	contain form dis ed, Dispo	plays a cu sed of, or Be evertible sec	orm are not rently valid neficially Ovarrities)	required d OMB co	to respond ntrol numb	d unless the	e	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year)		Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
					-										
				Code	V	(A)	(D)	Date Exercisal	Expiratio le Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Restricted Stock Units	\$ 0	07/08/2021		Code		(A) 8,572	(D)			Title Common	or Number of Shares	\$ 0		(Instr. 4)	
Stock	\$ 0 \$ 0	07/08/2021					(D)	Exercisal	le Date	Common	or Number of Shares		(Instr. 4)		

		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Guy Wendy C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Administrative Officer				

Signatures

/s/ Wendy Guy by Michael B. Kirwan, as Attorney-in-Fact	07/09/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The restricted stock units vest in two equal installments beginning July 1, 2022.
- (2) The Restricted Stock Units vest upon achievement of certain performance goals.
- (3) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.